What is the mechanism of resistance by lactamases to â-lactam antibiotics?

Explanation

## Correct Answer: D. Degradation of antibiotics β-lactamases are bacterial enzymes that confer resistance to β-lactam antibiotics through a direct enzymatic mechanism: **hydrolysis of the β-lactam ring**. The β-lactam ring is the critical structural moiety that binds to penicillin-binding proteins (PBPs) and inhibits bacterial cell wall synthesis. β-lactamases cleave the amide bond in this ring, permanently inactivating the antibiotic and rendering it unable to bind PBPs. This is not a passive resistance mechanism—it is active enzymatic degradation. The enzyme catalyzes the opening of the lactam ring, converting the antibiotic into an inactive metabolite. This mechanism explains why β-lactamase-producing organisms (e.g., *Staphylococcus aureus*, *Haemophilus influenzae*, *Neisseria gonorrhoeae*) are resistant to penicillins and cephalosporins unless protected by β-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam). In Indian clinical practice, MRSA and ESBL-producing Gram-negatives are major concerns in hospital settings, and understanding this degradation mechanism is critical for appropriate antibiotic selection and the rationale for using inhibitor combinations. ## Why the other options are wrong **A. Drug efflux** — This is wrong because drug efflux is a resistance mechanism for fluoroquinolones, macrolides, and tetracyclines—not β-lactams. Efflux pumps actively pump antibiotics out of the cell, but β-lactamases work by enzymatic degradation of the drug itself, not by removing it from the cell. NBE may trap students who confuse general resistance mechanisms without distinguishing the specific mechanism for each drug class. **B. Alteration in 50s ribosome structure** — This is wrong because 50S ribosomal alterations confer resistance to macrolides, chloramphenicol, and linezolid—not β-lactams. β-lactams do not target the ribosome; they target PBPs and cell wall synthesis. This option represents a completely different resistance mechanism and drug target. NBE pairs this to test whether students confuse bacterial resistance mechanisms across different antibiotic classes. **C. Alteration of penicillin binding protein** — This is wrong because PBP alteration is the mechanism of resistance in MRSA and pneumococci (altered PBPs prevent antibiotic binding), not the mechanism of β-lactamase resistance. While β-lactamases protect PBPs by destroying the antibiotic before it reaches them, the resistance mechanism itself is enzymatic degradation, not PBP modification. This is a classic NBE trap: students may confuse the target (PBP) with the resistance mechanism (degradation). ## High-Yield Facts - **β-lactamases** are serine proteases that hydrolyze the β-lactam ring, rendering the antibiotic inactive and unable to bind PBPs. - **β-lactamase inhibitors** (clavulanic acid, sulbactam, tazobactam) are irreversible inhibitors used in combination with β-lactams to overcome this resistance in India. - **ESBL-producing Gram-negatives** and **MRSA** are major causes of hospital-acquired infections in India; β-lactamase production is a key resistance mechanism. - **Cephalosporins** are more resistant to some β-lactamases than penicillins due to structural differences, but broad-spectrum β-lactamases (ESBLs, AmpC) can degrade both. - **Carbapenems** are resistant to most β-lactamases except metallo-β-lactamases (MBLs), which are emerging in India and confer resistance to meropenem and imipenem. ## Mnemonics **LASE = Lactamase Attacks Structural Element** Lactamase = enzyme that breaks (hydrolyzes) the lactam ring. Remember: **LASE** = **L**actam **A**ttack by **S**erine **E**nzyme. The serine residue in the active site nucleophilically attacks the β-lactam ring, opening it and destroying the drug. **β-lactamase = β-lactam BREAKER (not blocker)** Students often confuse β-lactamase resistance with PBP alteration (which blocks binding). β-lactamase doesn't block—it **breaks** the drug. Think: **BREAKER** = **B**acterial **R**ing-**E**nzyme **A**cts to **K**ill **E**ffectiveness **R**apidly. ## NBE Trap NBE pairs β-lactamase with "alteration of PBP" to trap students who know that PBPs are the target of β-lactams but confuse the resistance mechanism. β-lactamases destroy the drug *before* it reaches PBPs (degradation), whereas MRSA has altered PBPs that the drug cannot bind (modification)—these are distinct mechanisms. ## Clinical Pearl In Indian hospitals, when a patient with a β-lactamase-producing *Staphylococcus aureus* or ESBL-producing *E. coli* infection fails amoxicillin or ceftriaxone monotherapy, adding a β-lactamase inhibitor (amoxicillin-clavulanate, piperacillin-tazobactam) restores efficacy by protecting the antibiotic from enzymatic degradation—a direct clinical application of understanding this mechanism. _Reference: KD Tripathi Pharmacology Ch. 45 (Antimicrobials); Jawetz Microbiology Ch. 10 (Bacterial Resistance)_